Conference item
High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant
- Abstract:
- It remains a global health priority to develop a durable and highly efficacious malaria vaccine. The most advanced malaria vaccine candidate, RTS,S/AS01 has completed Phase III testing in a multicentre study across several African sites and demonstrates low-level (~30%) efficacy against clinical malaria in children aged 5-17 months after a three dose schedule. Efficacy wanes rapidly over time and there remain some safety concerns that require further assessment in the planned pilot deployment trials due to commence in Africa in 2018.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 428.6KB, Terms of use)
-
- Publisher copy:
- 10.4269/ajtmh.abstract2017
Authors
- Publisher:
- American Society of Tropical Medicine and Hygiene
- Host title:
- 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH 2017)
- Journal:
- 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ATMH 2017) More from this journal
- Publication date:
- 2017-11-01
- DOI:
- Pubs id:
-
pubs:822985
- UUID:
-
uuid:e433efac-8e80-4278-b303-3537df06b9f7
- Local pid:
-
pubs:822985
- Source identifiers:
-
822985
- Deposit date:
-
2018-08-30
Terms of use
- Copyright holder:
- American Society of Tropical Medicine and Hygiene
- Copyright date:
- 2017
- Notes:
- © The American Society of Tropical Medicine and Hygiene. This is the published version of the abstract. This version is also available online from the American Society of Tropical Medicine and Hygiene at: https://doi.org/10.4269/ajtmh.abstract2017
If you are the owner of this record, you can report an update to it here: Report update to this record